면역관문억제제 시장 규모, 점유율, 동향 분석 보고서 : 유형별, 용도별, 유통 채널별, 지역별, 부문별 예측(2024-2030년)

Immune Checkpoint Inhibitors Market Size, Share & Trends Analysis Report By Type (PD-1, PD-L1, CTLA-4), By Application (Lung Cancer, Breast Cancer, Melanoma), By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030

US $ 5,950 ￦ 8,609,000

Unprintable PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,950 ￦ 10,055,000

Printable PDF (5-User License)

PDF 보고서를 동일 기업의 5명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,950 ￦ 12,949,000

Printable PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

면역관문억제제 시장 성장 및 동향:

Grand View Research, Inc.의 최신 보고서에 따르면, 면역관문억제제 세계 시장 규모는 2030년까지 1,542억 5,000만 달러에 달할 것으로 예상되며, 2024년부터 2030년까지 CAGR은 17.9%로 성장할 것으로 예상됩니다.

시장 성장의 원동력은 암 유병률의 증가와 면역관문억제제의 FDA 승인 증가에 기인합니다. 또한, 연구 기관 및 주요 사업자들의 연구개발 활동 증가와 함께 암 면역요법을 촉진하기 위한 자금이 증가하면서 시장 성장을 더욱 촉진하고 있습니다.

다발성 암의 유병률 증가와 적절한 치료 옵션에 대한 수요 증가는 시장 성장을 촉진할 것으로 예상됩니다. 예를 들어, 국제암연구소(IARC)에 따르면 2023년에는 2,070만 명 이상의 새로운 암 환자가 발생할 것으로 예상됩니다. 또한, Breast Cancer Statistics and Resources에 따르면 2020년 전 세계적으로 약 230만 명의 여성이 유방암 진단을 받았다고 합니다. 또한, 화학요법과 방사선 치료의 부작용에 대한 의료진과 환자들의 인식이 높아지면서 면역관문억제제와 같은 대체 치료제의 성장에 영향을 미치는 주요 요인이 되고 있습니다.

암 면역치료에 대한 자금 지원의 증가는 가까운 장래에 암 면역치료 시장에 유리한 기회를 제공할 것으로 예상됩니다. 정부와 주요 기관은 면역관문억제제를 포함한 암 면역요법 개발을 위한 연구개발 활동을 장려함으로써 암 면역요법에 대한 의료비 지출을 억제하기 위한 활동을 지속적으로 추진하고 있습니다. 예를 들어, 2023년 7월, 암 연구소는 면역 치료 기술 혁신을 촉진하기 위해 약 2,800만 달러의 보조금을 수여했습니다. 마찬가지로 2021년 7월, 랭킨 정부는 면역관문억제제를 포함한 암 치료를 개선하기 위해 1,800만 달러의 투자를 발표했습니다. 이러한 노력은 시장 성장을 촉진하고 있습니다.

그러나 암 치료에서 면역관문억제제의 높은 비용과 합병증은 큰 문제점으로 지적되고 있습니다. 암 치료를 위한 면역관문억제제는 면역 관련 부작용을 유발할 수 있습니다. 이러한 합병증에는 피부 문제, 대장염과 같은 위장 장애, 내분비 기능 장애, 폐렴, 류마티스 증상, 신경계 및 심장 합병증, 신장 문제 등이 포함되며, ICI는 암에 큰 영향을 미치는데, 이러한 부작용은 예측 기간 동안 시장 성장에 장애가 될 것으로 예상됩니다.

면역관문억제제 시장 보고서 하이라이트

• 제품 유형별로는 펨브롤리주맙, 니볼루맙 등 펨브롤리주맙, 니볼루맙 등 약물 처방이 급증하면서 PD-1 분야가 2023년 73.3%의 최대 매출 점유율을 기록하며 시장을 주도했습니다.
• 용도별로는 폐암 분야가 2023년 25.41%로 가장 큰 매출 점유율을 차지했습니다. 폐암 환자 수의 증가는 이 부문의 성장을 촉진하는 중요한 요인입니다.
• 용도별로는 대장암 분야가 예측 기간 동안 가장 빠른 CAGR로 성장할 것으로 예상됩니다.
• 유통 채널별로는 온라인 약국 분야가 의약품 조달의 접근성과 편의성 향상으로 인해 예측 기간 동안 가장 빠른 CAGR로 성장할 것으로 예상됩니다.
• 북미는 암 유병률 증가, 높은 구매력 평가, 양질의 의료 서비스에 대한 정부 지원, 상환 가능성 등의 요인으로 인해 2023년 매출 점유율 62.81%를 차지하며 시장을 주도했습니다.
• 2023년 3월, 바이오엔텍은 OncoC4와 전략적 제휴를 맺고 여러 고형암을 적응증으로 하는 신규 면역관문억제제 항CTLA-4 단클론항체 후보물질의 공동 개발 및 상용화를 시작했습니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 면역관문억제제 시장 변수, 동향, 범위

• 시장 계통 전망
  • 상부 시장 전망
  • 관련/부수 시장 전망
• 시장 역학
  • 시장 견인 요인 분석
  • 시장 성장 억제요인 분석
• 면역관문억제제 시장 분석 툴
  • 업계 분석 - Porter's Five Forces 분석
  • PESTEL 분석
  • 가격 분석
  • 파이프라인 분석

제4장 면역관문억제제 시장 : 유형 추정·동향 분석

• 세계의 면역관문억제제 시장 : 유형 대시보드
• 세계의 면역관문억제제 시장 : 유형 변동 분석
• 유형별, 매출
• PD-1
• PD-L1
• CTLA-4
• 기타

제5장 면역관문억제제 시장 : 용도 추정·동향 분석

• 세계의 면역관문억제제 시장 : 용도 대시보드
• 세계의 면역관문억제제 시장 : 용도 변동 분석
• 용도별, 매출
• 폐암
• 유방암
• 방광암
• 악성 흑색종
• 자궁경부암
• 호지킨림프종
• 대장암
• 기타

제6장 면역관문억제제 시장 : 유통 채널 추정·동향 분석

• 세계의 면역관문억제제 시장 : 유통 채널 대시보드
• 세계의 면역관문억제제 시장 : 유통 채널 변동 분석
• 유통 채널별, 매출
• 병원 약국
• 소매 약국
• 온라인 약국

제7장 면역관문억제제 시장 : 지역 추정·동향 분석

• 지역별 시장 점유율 분석, 2023년 및 2030년
• 지역 시장 대시보드
• 세계 지역 시장 현황
• 시장 규모, 예측 동행 분석, 2018-2030년 :
• 북미
  • 미국
  • 캐나다
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 노르웨이
  • 스웨덴
  • 덴마크
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 호주
  • 한국
  • 태국
• 라틴아메리카
  • 브라질
  • 멕시코
  • 아르헨티나
• 중동 및 아프리카
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트
  • 쿠웨이트

제8장 경쟁 상황

• 주요 시장 진출 기업에 의한 최근의 동향과 영향 분석
• 기업/경쟁 분류
• 벤더 상황
  • 주요 유통업체 및 채널 파트너 리스트
  • 주요 고객
  • 주요 기업의 시장 점유율 분석, 2023년
  • Sanofi
  • F. Hoffmann-La Roche Ltd.
  • Merck &Co.
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • Regeneron Pharmaceuticals Inc.
  • AstraZeneca PLC
  • Shanghai Jhunsi Biosciences Ltd
  • Immutep Ltd
  • BeiGene Ltd
  • GlaxoSmithKline PLC

ksm

영문 목차

영문목차

Immune Checkpoint Inhibitors Market Growth & Trends:

The global immune checkpoint inhibitors market size is anticipated to reach USD 154.25 billion by 2030 and is projected to grow at a CAGR of 17.9% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market growth is driven by increasing prevalence of cancer, and growing FDA approvals of immune checkpoint inhibitors. Moreover, increasing funding for advancing cancer immunotherapy coupled with rising R&D activities by research institutes and key operating players are further impelling market growth.

The rise in prevalence of multiple cancers and increase in need for appropriate treatment options are anticipated to drive market growth. For instance, according to the International Agency for Research on Cancer (IARC), over 20.7 million new cancer cases were expected in 2023.In addition, according to the Breast Cancer Statistics and Resources, about 2.3 million women were diagnosed with breast cancer across the globe in 2020. Moreover, increased awareness among healthcare providers and patients about the adverse effects of chemotherapy & radiation therapy is a primary factor influencing the growth of alternative therapeutics, such as immune checkpoint inhibitors.

Growing funding for cancer immunotherapy is anticipated to offer lucrative opportunities for the market in the near future. Government and key organizations engage constantly in activities intended at curbing cancer immunotherapy healthcare expenditure by encouraging R&D activities to advance cancer immunotherapy including immune checkpoint inhibitors. For instance, in July 2023, the Cancer Research Institute awarded about USD 28 million in grants to boost innovations in immunotherapy. Similarly, in July 2021, the Rankin government announced an investment of USD 18 million to improve cancer therapy including immune checkpoint inhibitors. Such initiatives are driving market growth.

However, the high cost associated and complications of immune checkpoint inhibitors in cancer therapy pose a significant challenge. Immune checkpoint inhibitors for cancer treatment can lead to immune-related adverse events. These complications include skin issues, gastrointestinal problems like colitis, endocrine dysfunctions, pulmonary inflammation, rheumatologic symptoms, nervous system and cardiac complications, and renal issues. Although ICIs show significant success against cancer, these side effects are anticipated to hamper market growth during the forecast period.

Immune Checkpoint Inhibitors Market Report Highlights:

• Based on type, the PD-1 segment led the market with the largest revenue share of 73.3% in 2023, owing to growing R&D activities, increasing product approvals and surge in prescription of drugs such as pembrolizumab and nivolumab
• Based on application, the lung cancer segment held the market with the largest revenue share of 25.41% in 2023. Increase in number of lung cancer cases is a significant factor driving growth of this segment
• Based on application, the colorectal cancer segment is expected to grow at the fastest CAGR over forecast period
• Based on the distribution channel, the online pharmacy segment is expected to grow at the fastest CAGR over the forecast period, owing to the increasing accessibility and convenience of drug procurement
• North America dominated the market with the revenue share of 62.81% in 2023, owing to factors such as increasing prevalence of cancer, high purchasing power parity, government support for quality healthcare, and availability of reimbursement
• In March 2023, BioNTech, entered into strategic collaboration with OncoC4 to co-develop and commercialize new immune checkpoint inhibitor anti-CTLA-4 monoclonal antibody candidate for multiple solid tumor indications.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Type
  • 1.2.2. Application
  • 1.2.3. End Use
  • 1.2.4. Regional scope
  • 1.2.5. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in Asia Pacific
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Type outlook
  • 2.2.2. Application outlook
  • 2.2.3. End Use outlook
  • 2.2.4. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Immune Checkpoint Inhibitors Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Increasing prevalence of cancer
    • 3.2.1.2. Increasing R&D investments
    • 3.2.1.3. Rise in healthcare spending
    • 3.2.1.4. New product approvals and launches
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High cost of immune checkpoint inhibitors
• 3.3. Immune Checkpoint Inhibitors Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape
  • 3.3.3. Pricing Analysis
  • 3.3.4. Pipeline Analysis

Chapter 4. Immune Checkpoint Inhibitors Market: Type Estimates & Trend Analysis

• 4.1. Global Immune Checkpoint Inhibitors Market: Type Dashboard
• 4.2. Global Immune Checkpoint Inhibitors Market: Type Movement Analysis
• 4.3. Global Immune Checkpoint Inhibitors Market Estimates and Forecasts, by Type, Revenue (USD Million)
• 4.4. PD-1
  • 4.4.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
• 4.5. PD-L1
  • 4.5.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
• 4.6. CTLA-4
  • 4.6.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
• 4.7. Others
  • 4.7.1. Market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Immune Checkpoint Inhibitors Market: Application Estimates & Trend Analysis

• 5.1. Global Immune Checkpoint Inhibitors Market: Application Dashboard
• 5.2. Global Immune Checkpoint Inhibitors Market: Application Movement Analysis
• 5.3. Global Immune Checkpoint Inhibitors Market Estimates and Forecasts, by Application, Revenue (USD Million)
• 5.4. Lung Cancer
  • 5.4.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
• 5.5. Breast Cancer
  • 5.5.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
• 5.6. Bladder Cancer
  • 5.6.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
• 5.7. Melanoma
  • 5.7.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
• 5.8. Cervical Cancer
  • 5.8.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
• 5.9. Hodgkin Lymphoma Cancer
  • 5.9.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
• 5.10. Colorectal Cancer
  • 5.10.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
• 5.11. Others
  • 5.11.1. Market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. Immune Checkpoint Inhibitors Market: Distribution Channel Estimates & Trend Analysis

• 6.1. Global Immune Checkpoint Inhibitors Market: Distribution Channel Dashboard
• 6.2. Global Immune Checkpoint Inhibitors Market: Distribution Channel Movement Analysis
• 6.3. Global Immune Checkpoint Inhibitors Market Estimates and Forecasts, by Distribution Channel, Revenue (USD Million)
• 6.4. Hospital Pharmacies
  • 6.4.1. Market estimates and forecasts, 2018 to 2030 (USD million)
• 6.5. Retail Pharmacies
  • 6.5.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
• 6.6. Online Pharmacies
  • 6.6.1. Market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 7. Immune Checkpoint Inhibitors Market: Regional Estimates & Trend Analysis

• 7.1. Regional Market Share Analysis, 2023 & 2030
• 7.2. Regional Market Dashboard
• 7.3. Global Regional Market Snapshot
• 7.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 7.5. North America
  • 7.5.1. U.S.
    • 7.5.1.1. Key country dynamics
    • 7.5.1.2. Regulatory framework/ reimbursement structure
    • 7.5.1.3. Competitive scenario
    • 7.5.1.4. U.S. market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.5.2. Canada
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Regulatory framework/ reimbursement structure
    • 7.5.2.3. Competitive scenario
    • 7.5.2.4. Canada market estimates and forecasts, 2018 to 2030 (USD Million)
• 7.6. Europe
  • 7.6.1. UK
    • 7.6.1.1. Key country dynamics
    • 7.6.1.2. Regulatory framework/ reimbursement structure
    • 7.6.1.3. Competitive scenario
    • 7.6.1.4. UK market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.6.2. Germany
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Regulatory framework/ reimbursement structure
    • 7.6.2.3. Competitive scenario
    • 7.6.2.4. Germany market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.6.3. France
    • 7.6.3.1. Key country dynamics
    • 7.6.3.2. Regulatory framework/ reimbursement structure
    • 7.6.3.3. Competitive scenario
    • 7.6.3.4. France market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.6.4. Italy
    • 7.6.4.1. Key country dynamics
    • 7.6.4.2. Regulatory framework/ reimbursement structure
    • 7.6.4.3. Competitive scenario
    • 7.6.4.4. Italy market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.6.5. Spain
    • 7.6.5.1. Key country dynamics
    • 7.6.5.2. Regulatory framework/ reimbursement structure
    • 7.6.5.3. Competitive scenario
    • 7.6.5.4. Spain market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.6.6. Norway
    • 7.6.6.1. Key country dynamics
    • 7.6.6.2. Regulatory framework/ reimbursement structure
    • 7.6.6.3. Competitive scenario
    • 7.6.6.4. Norway market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.6.7. Sweden
    • 7.6.7.1. Key country dynamics
    • 7.6.7.2. Regulatory framework/ reimbursement structure
    • 7.6.7.3. Competitive scenario
    • 7.6.7.4. Sweden market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.6.8. Denmark
    • 7.6.8.1. Key country dynamics
    • 7.6.8.2. Regulatory framework/ reimbursement structure
    • 7.6.8.3. Competitive scenario
    • 7.6.8.4. Denmark market estimates and forecasts, 2018 to 2030 (USD Million)
• 7.7. Asia Pacific
  • 7.7.1. Japan
    • 7.7.1.1. Key country dynamics
    • 7.7.1.2. Regulatory framework/ reimbursement structure
    • 7.7.1.3. Competitive scenario
    • 7.7.1.4. Japan market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.7.2. China
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Regulatory framework/ reimbursement structure
    • 7.7.2.3. Competitive scenario
    • 7.7.2.4. China market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.7.3. India
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Regulatory framework/ reimbursement structure
    • 7.7.3.3. Competitive scenario
    • 7.7.3.4. India market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.7.4. Australia
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Regulatory framework/ reimbursement structure
    • 7.7.4.3. Competitive scenario
    • 7.7.4.4. Australia market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.7.5. South Korea
    • 7.7.5.1. Key country dynamics
    • 7.7.5.2. Regulatory framework/ reimbursement structure
    • 7.7.5.3. Competitive scenario
    • 7.7.5.4. South Korea market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.7.6. Thailand
    • 7.7.6.1. Key country dynamics
    • 7.7.6.2. Regulatory framework/ reimbursement structure
    • 7.7.6.3. Competitive scenario
    • 7.7.6.4. Thailand market estimates and forecasts, 2018 to 2030 (USD Million)
• 7.8. Latin America
  • 7.8.1. Brazil
    • 7.8.1.1. Key country dynamics
    • 7.8.1.2. Regulatory framework/ reimbursement structure
    • 7.8.1.3. Competitive scenario
    • 7.8.1.4. Brazil market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.8.2. Mexico
    • 7.8.2.1. Key country dynamics
    • 7.8.2.2. Regulatory framework/ reimbursement structure
    • 7.8.2.3. Competitive scenario
    • 7.8.2.4. Mexico market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.8.3. Argentina
    • 7.8.3.1. Key country dynamics
    • 7.8.3.2. Regulatory framework/ reimbursement structure
    • 7.8.3.3. Competitive scenario
    • 7.8.3.4. Argentina market estimates and forecasts, 2018 to 2030 (USD Million)
• 7.9. MEA
  • 7.9.1. South Africa
    • 7.9.1.1. Key country dynamics
    • 7.9.1.2. Regulatory framework/ reimbursement structure
    • 7.9.1.3. Competitive scenario
    • 7.9.1.4. South Africa market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.9.2. Saudi Arabia
    • 7.9.2.1. Key country dynamics
    • 7.9.2.2. Regulatory framework/ reimbursement structure
    • 7.9.2.3. Competitive scenario
    • 7.9.2.4. Saudi Arabia market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.9.3. UAE
    • 7.9.3.1. Key country dynamics
    • 7.9.3.2. Regulatory framework/ reimbursement structure
    • 7.9.3.3. Competitive scenario
    • 7.9.3.4. UAE market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.9.4. Kuwait
    • 7.9.4.1. Key country dynamics
    • 7.9.4.2. Regulatory framework/ reimbursement structure
    • 7.9.4.3. Competitive scenario
    • 7.9.4.4. Kuwait market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Market Participants
• 8.2. Company/Competition Categorization
• 8.3. Vendor Landscape
  • 8.3.1. List of key distributors and channel partners
  • 8.3.2. Key customers
  • 8.3.3. Key company market share analysis, 2023
  • 8.3.4. Sanofi
    • 8.3.4.1. Company overview
    • 8.3.4.2. Financial performance
    • 8.3.4.3. Product benchmarking
    • 8.3.4.4. Strategic initiatives
  • 8.3.5. F. Hoffmann-La Roche Ltd.
    • 8.3.5.1. Company overview
    • 8.3.5.2. Financial performance
    • 8.3.5.3. Product benchmarking
    • 8.3.5.4. Strategic initiatives
  • 8.3.6. Merck & Co.
    • 8.3.6.1. Company overview
    • 8.3.6.2. Financial performance
    • 8.3.6.3. Product benchmarking
    • 8.3.6.4. Strategic initiatives
  • 8.3.7. Bristol-Myers Squibb Company
    • 8.3.7.1. Company overview
    • 8.3.7.2. Financial performance
    • 8.3.7.3. Product benchmarking
    • 8.3.7.4. Strategic initiatives
  • 8.3.8. Eli Lilly and Company
    • 8.3.8.1. Company overview
    • 8.3.8.2. Financial performance
    • 8.3.8.3. Product benchmarking
    • 8.3.8.4. Strategic initiatives
  • 8.3.9. Regeneron Pharmaceuticals Inc.
    • 8.3.9.1. Company overview
    • 8.3.9.2. Financial performance
    • 8.3.9.3. Product benchmarking
    • 8.3.9.4. Strategic initiatives
  • 8.3.10. AstraZeneca PLC
    • 8.3.10.1. Company overview
    • 8.3.10.2. Financial performance
    • 8.3.10.3. Product benchmarking
    • 8.3.10.4. Strategic initiatives
  • 8.3.11. Shanghai Jhunsi Biosciences Ltd
    • 8.3.11.1. Company overview
    • 8.3.11.2. Financial performance
    • 8.3.11.3. Product benchmarking
    • 8.3.11.4. Strategic initiatives
  • 8.3.12. Immutep Ltd
    • 8.3.12.1. Company overview
    • 8.3.12.2. Financial performance
    • 8.3.12.3. Product benchmarking
    • 8.3.12.4. Strategic initiatives
  • 8.3.13. BeiGene Ltd
    • 8.3.13.1. Company overview
    • 8.3.13.2. Financial performance
    • 8.3.13.3. Product benchmarking
    • 8.3.13.4. Strategic initiatives
  • 8.3.14. GlaxoSmithKline PLC
    • 8.3.14.1. Company overview
    • 8.3.14.2. Financial performance
    • 8.3.14.3. Product benchmarking
    • 8.3.14.4. Strategic initiatives

관련자료